HCC-话题@MedSci

#HCC#

114篇内容 | 5774人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1259516, encodeId=a58f125951685, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Cell Death Differentiation：抑癌锌指同源盒2（ZHX2）在NAFLD发展成HCC的过程中的作用, objectType=article, longId=183620, objectId=bf1d18362012, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf1d18362012, replyNumber=0, likeNumber=79, createdTime=2019-11-27, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf1d18362012, moduleTitle=Cell Death Differentiation：抑癌锌指同源盒2（ZHX2）在NAFLD发展成HCC的过程中的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf1d18362012)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259515, encodeId=4b5c1259515ba, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=JCO：东方肝胆外科医院程树群教授团队发文：三维适形新辅助放疗显著改善可切除HCC伴PVTT患者的OS, objectType=article, longId=175184, objectId=78551e518428, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78551e518428, replyNumber=0, likeNumber=76, createdTime=2019-07-12, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78551e518428, moduleTitle=JCO：东方肝胆外科医院程树群教授团队发文：三维适形新辅助放疗显著改善可切除HCC伴PVTT患者的OS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78551e518428)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259514, encodeId=c8ce1259514ff, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=周爱萍教授深入解读KEYNOTE-240研究：进一步证实帕博利珠单抗HCC二线标准治疗地位, objectType=article, longId=174829, objectId=8b6f1e482903, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b6f1e482903, replyNumber=0, likeNumber=72, createdTime=2019-07-06, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b6f1e482903, moduleTitle=周爱萍教授深入解读KEYNOTE-240研究：进一步证实帕博利珠单抗HCC二线标准治疗地位, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b6f1e482903)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259513, encodeId=5efb125951322, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=【2019 ASCO】破解HCC术后复发难题，中国智慧闪耀国际舞台, objectType=article, longId=168219, objectId=67eb168219fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67eb168219fd, replyNumber=0, likeNumber=43, createdTime=2019-06-14, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67eb168219fd, moduleTitle=【2019 ASCO】破解HCC术后复发难题，中国智慧闪耀国际舞台, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67eb168219fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259512, encodeId=cb1512595128c, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=达伯舒®联合抗VEGF单抗用于一线HCC的研究完成首例患者给药, objectType=article, longId=161437, objectId=0fed16143ef7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0fed16143ef7, replyNumber=0, likeNumber=76, createdTime=2019-03-02, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0fed16143ef7, moduleTitle=达伯舒®联合抗VEGF单抗用于一线HCC的研究完成首例患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0fed16143ef7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259511, encodeId=2ba812595116a, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=J Hepatology：直接作用抗病毒药物与干扰素对HCV相关HCC早期复发的影响无差异, objectType=article, longId=156075, objectId=86e41560e596, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86e41560e596, replyNumber=0, likeNumber=71, createdTime=2018-12-19, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86e41560e596, moduleTitle=J Hepatology：直接作用抗病毒药物与干扰素对HCV相关HCC早期复发的影响无差异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86e41560e596)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259510, encodeId=9d461259510ef, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Nucleic Acids Res：RNA结合蛋白RPS3影响HCC进展, objectType=article, longId=155408, objectId=25bc15540833, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25bc15540833, replyNumber=0, likeNumber=80, createdTime=2018-12-10, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25bc15540833, moduleTitle=Nucleic Acids Res：RNA结合蛋白RPS3影响HCC进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25bc15540833)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259509, encodeId=f14812595098f, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Hepatology：血管生成素2是CHC患者接受DAA治疗后，HCC复发或新发的重要预测因素, objectType=article, longId=149526, objectId=cefb1495267d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cefb1495267d, replyNumber=0, likeNumber=85, createdTime=2018-09-26, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cefb1495267d, moduleTitle=Hepatology：血管生成素2是CHC患者接受DAA治疗后，HCC复发或新发的重要预测因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cefb1495267d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259508, encodeId=63951259508ce, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Hepatology：DAA没有增加HCC局部治疗患者的HCC复发风险，且能够降低因肿瘤进展或死亡而导致退出等待肝移植名单的风险, objectType=article, longId=147979, objectId=e62714e97924, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e62714e97924, replyNumber=0, likeNumber=82, createdTime=2018-09-02, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e62714e97924, moduleTitle=Hepatology：DAA没有增加HCC局部治疗患者的HCC复发风险，且能够降低因肿瘤进展或死亡而导致退出等待肝移植名单的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e62714e97924)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259507, encodeId=6796125950e8e, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=J Hepatol：在HCV患者抗病毒治疗后，开发出一种可以患者发生HCC风险的模型, objectType=article, longId=147741, objectId=96b614e7416e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96b614e7416e, replyNumber=0, likeNumber=67, createdTime=2018-08-31, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96b614e7416e, moduleTitle=J Hepatol：在HCV患者抗病毒治疗后，开发出一种可以患者发生HCC风险的模型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96b614e7416e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259506, encodeId=82d31259506e9, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=J Hepatol：DAA治疗晚期肝纤维化的HCV患者，其新生HCC的发生率, objectType=article, longId=145191, objectId=71ff14519145, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71ff14519145, replyNumber=0, likeNumber=92, createdTime=2018-07-27, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71ff14519145, moduleTitle=J Hepatol：DAA治疗晚期肝纤维化的HCV患者，其新生HCC的发生率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=71ff14519145)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259505, encodeId=2e0b1259505e1, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Phenformin联合mTOR抑制剂在HCC中显示出治疗希望, objectType=article, longId=141922, objectId=863314192247, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=863314192247, replyNumber=0, likeNumber=90, createdTime=2018-06-30, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=863314192247, moduleTitle=Phenformin联合mTOR抑制剂在HCC中显示出治疗希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=863314192247)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259504, encodeId=a0171259504d8, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Liver Int：FABP4，通常在肝脏中不表达的FABP，可以由肝细胞和HCC细胞合成和分泌，可能会调节肿瘤进展, objectType=article, longId=140207, objectId=65b614020e9f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65b614020e9f, replyNumber=0, likeNumber=126, createdTime=2018-06-08, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65b614020e9f, moduleTitle=Liver Int：FABP4，通常在肝脏中不表达的FABP，可以由肝细胞和HCC细胞合成和分泌，可能会调节肿瘤进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65b614020e9f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259503, encodeId=aba81259503bb, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Liver Int：与病毒性HCC患者相比，隐型肝癌患者的肿瘤更大，肿瘤分期愈晚，总体生存率较低, objectType=article, longId=138154, objectId=208313815466, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=208313815466, replyNumber=0, likeNumber=71, createdTime=2018-05-16, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=208313815466, moduleTitle=Liver Int：与病毒性HCC患者相比，隐型肝癌患者的肿瘤更大，肿瘤分期愈晚，总体生存率较低, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=208313815466)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259502, encodeId=6714125950270, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Hepatology：重构肝细胞癌患者的治疗方法：采用HALTHCC进行纵向评估，改善了切除和等待策略, objectType=article, longId=134582, objectId=2f5c134582f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f5c134582f1, replyNumber=0, likeNumber=0, createdTime=2018-04-10, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f5c134582f1, moduleTitle=Hepatology：重构肝细胞癌患者的治疗方法：采用HALTHCC进行纵向评估，改善了切除和等待策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f5c134582f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259501, encodeId=99781259501e9, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=JAMA Oncol：传统治疗方式的“逆袭” :TACE+放疗治疗晚期HCC患者, objectType=article, longId=134331, objectId=97871343311c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97871343311c, replyNumber=0, likeNumber=72, createdTime=2018-04-06, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97871343311c, moduleTitle=JAMA Oncol：传统治疗方式的“逆袭” :TACE+放疗治疗晚期HCC患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97871343311c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259500, encodeId=022112595009c, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=J Hepatol：接受DAA治疗的HCV晚期患者，新发HCC比率不高，可能是先前显微、未发现的肿瘤, objectType=article, longId=133476, objectId=28c81334e64c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28c81334e64c, replyNumber=0, likeNumber=100, createdTime=2018-03-27, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28c81334e64c, moduleTitle=J Hepatol：接受DAA治疗的HCV晚期患者，新发HCC比率不高，可能是先前显微、未发现的肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28c81334e64c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259499, encodeId=05f51259499b6, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=JCO：局部晚期HCC患者是否推荐放射性栓塞治疗, objectType=article, longId=132144, objectId=b8ed13214436, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8ed13214436, replyNumber=0, likeNumber=84, createdTime=2018-03-13, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8ed13214436, moduleTitle=JCO：局部晚期HCC患者是否推荐放射性栓塞治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8ed13214436)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259498, encodeId=4d081259498e2, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Aliment Pharmacol Ther：常规监测的CHB患者HCC检测失败的预测因素, objectType=article, longId=131795, objectId=ac91131e9558, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac91131e9558, replyNumber=0, likeNumber=93, createdTime=2018-03-09, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac91131e9558, moduleTitle=Aliment Pharmacol Ther：常规监测的CHB患者HCC检测失败的预测因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac91131e9558)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259497, encodeId=2851125949e0a, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Radiology：DEB-TACE评估肿瘤生物学及肝细胞肝癌（HCC）5年移植复发率, objectType=article, longId=130176, objectId=d4551301e6b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4551301e6b1, replyNumber=0, likeNumber=71, createdTime=2018-02-20, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4551301e6b1, moduleTitle=Radiology：DEB-TACE评估肿瘤生物学及肝细胞肝癌（HCC）5年移植复发率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4551301e6b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

HCC

2020-05-29

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Cell Death Differentiation：抑癌锌指同源盒2（ZHX2）在NAFLD发展成HCC的过程中的作用

2019-11-27

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

JCO：东方肝胆外科医院程树群教授团队发文：三维适形新辅助放疗显著改善可切除HCC伴PVTT患者的OS

2019-07-12

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

周爱萍教授深入解读KEYNOTE-240研究：进一步证实帕博利珠单抗HCC二线标准治疗地位

2019-07-06

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

【2019 ASCO】破解HCC术后复发难题，中国智慧闪耀国际舞台

2019-06-14

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

达伯舒®联合抗VEGF单抗用于一线HCC的研究完成首例患者给药

2019-03-02

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

J Hepatology：直接作用抗病毒药物与干扰素对HCV相关HCC早期复发的影响无差异

2018-12-19

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Nucleic Acids Res：RNA结合蛋白RPS3影响HCC进展

2018-12-10

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Hepatology：血管生成素2是CHC患者接受DAA治疗后，HCC复发或新发的重要预测因素

2018-09-26

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Hepatology：DAA没有增加HCC局部治疗患者的HCC复发风险，且能够降低因肿瘤进展或死亡而导致退出等待肝移植名单的风险

2018-09-02

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

J Hepatol：在HCV患者抗病毒治疗后，开发出一种可以患者发生HCC风险的模型

2018-08-31

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

J Hepatol：DAA治疗晚期肝纤维化的HCV患者，其新生HCC的发生率

2018-07-27

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Phenformin联合mTOR抑制剂在HCC中显示出治疗希望

2018-06-30

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Liver Int：FABP4，通常在肝脏中不表达的FABP，可以由肝细胞和HCC细胞合成和分泌，可能会调节肿瘤进展

2018-06-08

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Liver Int：与病毒性HCC患者相比，隐型肝癌患者的肿瘤更大，肿瘤分期愈晚，总体生存率较低

2018-05-16

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Hepatology：重构肝细胞癌患者的治疗方法：采用HALTHCC进行纵向评估，改善了切除和等待策略

2018-04-10

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

JAMA Oncol：传统治疗方式的“逆袭” :TACE+放疗治疗晚期HCC患者

2018-04-06

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

J Hepatol：接受DAA治疗的HCV晚期患者，新发HCC比率不高，可能是先前显微、未发现的肿瘤

2018-03-27

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

JCO：局部晚期HCC患者是否推荐放射性栓塞治疗

2018-03-13

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

Aliment Pharmacol Ther：常规监测的CHB患者HCC检测失败的预测因素

2018-03-09

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

Radiology：DEB-TACE评估肿瘤生物学及肝细胞肝癌（HCC）5年移植复发率

2018-02-20

科室
- - 订阅+
  - 更多科室
工具
服务